Moderna, the vaccine's maker, announced Wednesday (Aug. 5) that a vaccine advisory committee to the FDA unanimously agreed that the shot is safe and effective for preventing illness from seasonal influenza. The shot, called mFlusiva or mRNA-1010, has been approved for people ages 50 and older.
The HA protein poses a major challenge for conventional flu vaccines because it mutates very rapidly as the viruses multiply and spread — and these existing vaccines take months to manufacture. That's one reason the resulting shots aren't always a great match for the flu viruses that end up circulating in any given year. A benefit of the mRNA platform is that vaccines can be produced very quickly and thus made to better match the season's dominant strains.
Of the 40,000 participants, about 970 got sick with flu, including 2% of the mRNA group and 2.8% of the standard group. That means the mRNA vaccine was 26.6% more protective than the conventional vaccine against illness from flu in this trial.
More people in the mRNA group experienced side effects like injection-site pain, headache, fatigue and achiness, compared with the standard group, but these effects were mostly short-lived and mild to moderate in severity. These side effects were consistent with what was seen in earlier trials of the vaccine.
RELATED STORIES
Nobel Prize in medicine goes to scientists who paved the way for COVID-19 mRNA vaccinesNew mRNA vaccine for deadly brain cancer triggers a strong immune responseAn experimental mRNA treatment counters immune cell aging in mice
"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors," Moderna CEO Stéphane Bancel said in a statement.
Under the second Trump administration, the federal government has been broadly retracting its support for mRNA vaccines, directly canceling hundreds of millions of dollars in funds for research and development and indirectly sending a chilling effect through the mRNA field, experts previously told Live Science. Even Moderna has been pulling back from investments, citing opposition from the U.S. market. Health Secretary Robert F. Kennedy Jr. has repeatedly voiced his opposition to mRNA technology.
This article is for informational purposes only and is not meant to offer medical advice.
Hence then, the article about fda approves first mrna vaccine for seasonal flu was published today ( ) and is available on Live Science ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves first mRNA vaccine for seasonal flu )
Also on site :
- GPGI, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GPGI
- Amazon’s 'Incredibly Soft' Lettuce-Trim Lounge Set Feels Like a Designer Brand That’s 8 Times the Price
- Quote of the Day: Big Little Feelings Founders Share the Parenting Lesson That Can Change How Kids See the World